We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Smartphone-Based Device Used for Influenza Virus Detection

By LabMedica International staff writers
Posted on 05 Aug 2019
Print article
Image: The device without a smartphone (left) and with a smartphone attached (right) (Photo courtesy of Rohan Mehra - Division for Strategic Public Relations).
Image: The device without a smartphone (left) and with a smartphone attached (right) (Photo courtesy of Rohan Mehra - Division for Strategic Public Relations).
A simple and inexpensive smartphone-based device was able to detect influenza virus particles in clinical samples with almost 100 times greater sensitivity than commercial rapid influenza diagnostic tests.

Droplet-based digital bioassays enable highly sensitive and quantitative analysis of biomolecules. However, digital bioassays generally require fluorescence microscopy techniques for detection, which are too large, expensive, and slow for point-of-care testing.

Investigators at the University of Tokyo (Japan) recently descibed an alternative method for detection of viruses in clinical samples. For this purpose, they developed a simple smartphone-based mobile imaging platform (23 × 10 cenitmeters × seven centimeters high) for digital point-of-care bioassays.

The device was designed to trap virus particles on a clear surface in microwells of 48 femtoliters capacity illuminated by an LED lamp. When a virus became trapped inside the microwell, the incident light from the LED was redirected upwards into the camera lens, manifesting as a bright pixel in an otherwise dark field.

The investigators used the smartphone device for digital influenza virus counting (DIViC) based on a fluorogenic assay for neuraminidase activity of the virus. Distinct fluorescence spots derived from single virus particles were observed. The number of detected fluorescence spots correlated well against the virus titer, suggesting that high sensitivity and quantification were achieved. On the other hand, the mobile platform detected only about 60% of influenza virus particles that could be identified by conventional fluorescence microscopy. Nonetheless, digital influenza virus counting with the mobile imaging platform still demonstrated 100 times greater sensitivity than could be obtained with a commercial rapid influenza test kit.

"I wanted to produce a useful tool for inaccessible or less-affluent communities that can help in the fight against diseases such as influenza," said first author Dr. Yoshihiro Minagawa, chief researcher in the faculty of engineering at the University of Tokyo. "Diagnosis is a critical factor of disease prevention. Our device paves the way for better access to essential diagnostic tools."

"Given two equal samples containing influenza, our system detected about 60% of the number of viruses as the fluorescence microscope. But it is much faster at doing so and more than adequate to produce good estimates for accurate diagnoses," said Dr. Minagawa. "What is really amazing is that our device is about 100 times more sensitive than a commercial rapid influenza test kit, and it is not just limited to that kind of virus. We also wish to add other biomarkers such as nucleic acids -- like DNA -- to the options of things the device can detect. This way we can maximize its usefulness to those on the front line of disease prevention, helping to save lives."

The smartphone-based virus detector was described in the July 17, 2019, online edition of the journal Lab on a Chip.

Related Links:
University of Tokyo

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.